Takeda sees return to growth within three years, new CEO says

Takeda Pharmaceutical is targeting a return on equity of at least 5% over that time, the company's newly appointed Chief Executive Officer Julie Kim said at her first news conference after assuming the top job this week. Takeda Pharmaceutical's newly appointed Chief Executive Officer Julie Kim says the company will return to growth in two to three years as it gears up for a wave of product launches. The company is targeting a return on equity of at least 5% over that time, Kim said at her first news conference after assuming the top job this week. Takeda is planning three major launches, including narcolepsy drug Oveporexton and psoriasis medication Zasocitinib in the next 12 months, while advancing a pipeline of five additional late-stage assets. It will ensure resiliency of its core therapeutic and business areas, which makes up more than half of its revenue. The company is also looking to leverage artificial intelligence, particularly in research and development, where it can accelerate the time it takes to run through pre-clinical work and improve decision making, according to Kim.